Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Condition(s) targeted: Rosacea

Intervention: Brimonidine (Drug); placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Actavis Inc.

Official(s) and/or principal investigator(s):
Nageshwar R Thudi, Ph.D., Study Director, Affiliation: Actavis Inc.

A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0. 33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (brimonidine) topical gel, 0. 33% (Galderma Laboratories, L. P., USA) in Patients with Moderate to Severe Facial Erythema Associated with Rosacea

Official title: A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: rosacea improvement or treatment success

Secondary outcome: Proportion of patients with a clinical response of treatment success on Day 1

Detailed description: Up to 462 patients 18 years of age and older, with confirmed clinical diagnosis of rosacea will be enrolled to have 413 in the modified intent-to-treat (mITT) population and 371 in the per-protocol (PP) population. Patients should have fewer than 3 facial inflammatory lesions, and moderate to severe erythema according to both Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA).

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male or non-pregnant, non-lactating female, 18 years of age or older. 2. Signed informed consent form, which meets all criteria of current FDA regulations. 3. Females of child bearing potential must not be pregnant or lactating at Screening and Randomization (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of childbearing potential must agree to the use of a reliable method of contraception (e. g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. A sterile sexual partner is not considered an adequate form of birth control. All females will be considered to be of childbearing potential unless they:

- Are post-menopausal, defined as women who have been amenorrheic for at least 12

consecutive months, without other known or suspected primary cause.

- Have been sterilized surgically or who are otherwise proven sterile (i. e., total

hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to Screening. Tubal ligation will not be considered a surgically sterile method. Female patients of childbearing potential are defined as:

- Women without prior hysterectomy, or who have had any evidence of menses in the

past 12 months.

- Females who have been amenorrhea for ≥ 12 months, but the amenorrhea is possibly

due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression. 4. Have a clinical diagnosis of facial rosacea and fewer than 3 inflammatory lesions on the face at Screening and at Randomization (before drug application on Day 1). 5. Have moderate to severe facial erythema according to both CEA and PSA (i. e., an erythema score of 3 or more for each of the CEA and PSA) at Screening and at Randomization (before drug application on Day 1). 6. Free from any systemic or dermatologic disorder (other than rosacea) that, in the opinion of the Investigator, will interfere with the study evaluations or increase the risk of AEs. 7. Willing to minimize external factors that might trigger rosacea flare-ups (e. g., hot environments, prolonged sun exposure, strong winds and emotional stress) within 24 hours of the Screening and Randomization visit. 8. Any skin type or race, providing the skin pigmentation will allow discernment of erythema. 9. Willingness and capability to cooperate to the extent and degree required by the protocol. Exclusion Criteria: 1. Patients with particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses similar to rosacea, such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia, that are present on the face (i. e., 5 areas: chin, nose, both cheeks, and forehead), that in the opinion of the Investigator would interfere with study evaluations. 2. Have 3 or more facial inflammatory lesions of rosacea. 3. Have an erythema score of 2 (mild), 1 (almost clear), or 0 (clear) on the CEA and/or the PSA at Screening and at Randomization (before drug application on Day 1). 4. Patients with excessive facial hair (beards, sideburns, mustaches, etc.) that would interfere with the diagnosis or assessment of rosacea. 5. Patients with moderate to severe telangiectasial masses in the 5 areas of the entire face: forehead, chin, nose and each cheek, that would interfere with study evaluations. 6. History of hypersensitivity or allergy to Mirvaso® including the active ingredient brimonidine tartarate or other component within the formulation. 7. Facial laser surgery for telangiectasia (or other conditions) within 6 weeks prior to randomization. 8. Exposed to excessive ultraviolet (UV) radiation within 1 week before screening or randomization visit and/or patient was unwilling to refrain from excessive exposure to UV radiation during the course of the study. 9. History of blood dyscrasia. 10. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression, or any other condition causing uncontrolled blood flow or blood pressure. 11. Females who are pregnant, lactating or likely to become pregnant during the study. 12. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participation. 13. Patients with severe, unstable or uncontrolled cardiovascular disease. 14. Patients who meet study restrictions at Screening and Randomization and/or unwillingness to comply with all restricted treatments 15. Receipt of any drug as part of a research study within 30 days before dosing. 16. Employees of the research center or Investigator. 17. Previous participation in this study. 18. Patients who are unable and/or unwilling to follow the study requirements, and procedures.

Investigator site 2, Hot Springs, Arkansas 71913, United States

Investigator site 16, Long Beach, California 90813, United States

Investigator site 5, Miami, Florida 33015, United States

Investigator site 7, Miami, Florida 33175, United States

Investigator site 8, Miramar, Florida 33027, United States

Investigator site 6, Ormond Beach, Florida 32174, United States

Investigator site 3, Carmel, Indiana 46032, United States

Investigator site 9, Louisville, Kentucky 40202, United States

Investigator site 14, Fridley, Minnesota 55432, United States

Investigator site 15, Henderson, Nevada 89052, United States

Investigator site 1, Albuquerque, New Mexico 87106, United States

Investigator site 10, High Point, North Carolina 27262, United States

Investigator site 11, Beachwood, Ohio 44122, United States

Investigator site 4, Nashville, Tennessee 37215, United States

Investigator site 13, College Station, Texas 77845, United States

Investigator site 12, Houston, Texas 77055, United States

Starting date: July 2014
Last updated: March 18, 2015